Koonings P P, Given F T
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk.
J Am Coll Surg. 1994 Feb;178(2):164-6.
A significant number of gynecologic oncologic patients require intravenous chemotherapy. Peripheral venous access frequently becomes difficult, necessitating reliable central venous access. This study was done to retrospectively review our experience with completely implanted venous access ports (ports). There were 100 women from 1984 to 1992 who received 115 ports. These ports remained in situ on average 350 +/- 2.3 days for a total of 110 patient years; 38 ports were in place for more than one year. An average of six courses of chemotherapy were given through each port. There was no statistically significant difference demonstrated in the complication rate secondary to site or side of placement (p = 0.5). Catheter performance in 77 percent of the patients was impeccable. We conclude that implantable ports are a safe and reliable method of chronic venous access in gynecologic oncologic patients requiring intravenous chemotherapy. Although ports reduce the number of complications and manipulations associated with percutaneous catheters, they are not devoid of problems.
相当一部分妇科肿瘤患者需要静脉化疗。外周静脉穿刺常常变得困难,因此需要可靠的中心静脉通路。本研究旨在回顾我们使用完全植入式静脉通路端口(端口)的经验。1984年至1992年期间,有100名女性接受了115个端口。这些端口平均在位350±2.3天,总计110患者年;38个端口在位超过一年。每个端口平均进行了六个疗程的化疗。放置部位或侧面继发的并发症发生率无统计学显著差异(p = 0.5)。77%的患者导管性能无可挑剔。我们得出结论,对于需要静脉化疗的妇科肿瘤患者,植入式端口是一种安全可靠的慢性静脉通路方法。尽管端口减少了与经皮导管相关的并发症和操作次数,但它们并非没有问题。